within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX53_Vosaroxin;

model Vosaroxin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.3333333333333332e-06,
    adminDuration = 600,
    adminMass = 72 / 1000000,
    adminCount = 1,
    Vd = 0.112,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.133,
    k12 = 7.361111111111111e-06,
    k21 = 7.361111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vosaroxin</td></tr><tr><td>ATC code:</td><td>L01XX53</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>72</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>112</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vosaroxin is an experimental anticancer quinolone derivative acting as a topoisomerase II inhibitor. It was being developed for the treatment of acute myeloid leukemia (AML) but is not approved for use; development was discontinued after phase III trials did not meet efficacy endpoints.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with relapsed or refractory acute myeloid leukemia after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XX53 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vosaroxin;
